Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InPedILD-ON: Long-term open-label nintedanib in children and adolescents with fibrosing interstitial lung disease
2020-005554-23Phase 3Active
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nintedanib in pulmonary fibrosis (PF) and respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), sponsored by Boehringer Ingelheim. Started Sep 2021; status: active.
02
Drugs
nintedanib
03
Conditions
pulmonary fibrosis (PF)respiratory bronchiolitis-associated interstitial lung disease (RB-ILD)
Beyond the preview
Go deeper on 2020-005554-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005554-23.